HomepagePRENW • NASDAQ
add
Prenetics
Vorige slotkoers
$Â 0,012
Dag-range
$Â 0,010 - $Â 0,012
Jaar-range
$Â 0,0042 - $Â 0,060
Beurswaarde
53,91Â mln. USD
Gem. volume
143,08K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 6,41Â mln. | -63,77% |
Bedrijfskosten | 12,94Â mln. | -35,05% |
Netto inkomsten | -8,57Â mln. | 21,92% |
Netto winstmarge | -133,60 | -115,48% |
Winst per aandeel | — | — |
EBITDA | -8,06Â mln. | 25,95% |
Effectief belastingtarief | 3,07% | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 71,26Â mln. | -62,57% |
Totale activa | 243,59Â mln. | -16,31% |
Totale passiva | 40,82Â mln. | -29,02% |
Totaal aandelenvermogen | 202,76 mln. | — |
Uitstaande aandelen | 12,22 mln. | — |
Koers-boekwaardeverhouding | 0,00 | — |
Rendement op activa | -9,20% | — |
Rendement op kapitaal | -10,98% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -8,57Â mln. | 21,92% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Opgericht
2014
Website
Werknemers
322